
In November 2024, Trace launched with a mission to develop genomic medicines for neurodegenerative diseases, starting with #ALS. Thank you to our team members and the patients, caregivers, advocates, and partners who’ve been part of these first two years. Here’s to building on this progress together. We're confident there is a better future ahead for those affected by ALS.

















